<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The recent identification of HER2 gene amplification as a novel predictor of resistance to the EGFR (HER2)-targeted antibody cetuximab and of response to combination therapies against EGFR and HER2 in <z:mp ids='MP_0002169'>wild-type</z:mp> KRAS <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> settings may represent a further step toward personalized medicine for patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Herein, we show that transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification is a molecular phenomenon that takes place in EGFR-dependent, <z:mp ids='MP_0002169'>wild-type</z:mp> KRAS <z:hpo ids='HP_0002860'>squamous cell carcinoma</z:hpo> (<z:mp ids='MP_0004207'>SCC</z:mp>) cells that acquire resistance to cetuximab </plain></SENT>
<SENT sid="2" pm="."><plain>Since cetuximab activity against cetuximab-refractory <z:mp ids='MP_0004207'>SCC</z:mp> cells can be fully restored in the presence of the anti-HER2 monoclonal antibody trastuzumab, our findings suggest that, beyond HER2 gene amplification, we might need to redefine the threshold values for HER2 positivity to improve the accuracy of the selection of cetuximab-refractory patients with <z:mp ids='MP_0002169'>wild-type</z:mp> KRAS that may benefit from receiving a cetuximab/trastuzumab combination </plain></SENT>
</text></document>